{
  "id": 10844940,
  "title": "Abeona Therapeutics CEO Seshadri sells $101,091 in shares",
  "url": "https://urgent.news/2026/09/30/abeona-therapeutics-ceo-seshadri-sells-101-091-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T02:45:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/abeona-therapeutics-ceo-seshadri-sells-101091-in-shares-93CH-4924044"
  },
  "original_language": "en",
  "account": "Vishwas Seshadri, CEO and director at Abeona Therapeutics Inc., divested 19,608 shares of the company's common stock on September 29, 2026. The sale, amounting to $101,091, took place at prices between $5.1150 and $5.3000 per share. Currently, the stock is trading at $5.16, experiencing a decline of nearly 7% over the past week. Despite this short-term dip, InvestingPro analysis suggests that the company is undervalued compared to its Fair Value. The transaction was primarily aimed at meeting tax obligations resulting from the vesting of restricted stock awards. Following the sale, Mr. Seshadri now holds a beneficial ownership of 1,286,500 shares of Abeona Therapeutics Inc. common stock. For comprehensive financial analysis and additional insights, investors can consult the Pro Research Report on InvestingPro. Additionally, recent financial results revealed a 31% increase in revenue from their lead therapy, ZEVASKYN, reaching $11.4 million for the second quarter, but falling short of the forecasted $12.24 million. The company reported a net loss of $20.2 million, or $0.35 per share, as it continues to expand its commercial launch and treatment-center network. Analysts have shown positive sentiment towards Abeona Therapeutics, with H.C. Wainwright maintaining a Buy rating with a $20 price target following the FDA approval of FAYUVI, and Cantor Fitzgerald raising their price target to $30, keeping an Overweight rating. Roth/MKM also initiated coverage with a Buy rating and $17 price target, emphasizing the robust prospects of ZEVASKYN.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Definium Therapeutics CEO Robert Barrow sells $1.15 million in shares",
        "url": "https://urgent.news/2026/09/30/definium-therapeutics-ceo-robert-barrow-sells-1-15-million-in-shares",
        "published": "2026-09-30T01:45:54.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}